These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 27061663)

  • 21. [News with clinical relevance from major scientific meetings 2014 - Update Urooncology].
    Hegele A; Skrobek L; Boegemann M
    Aktuelle Urol; 2015 Mar; 46(2):106-17. PubMed ID: 25909966
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU guidelines].
    Stenzl A; Cowan NC; De Santis M; Kuczyk MA; Merseburger AS; Ribal MJ; Sherif A; Witjes JA;
    Actas Urol Esp; 2012 Sep; 36(8):449-60. PubMed ID: 22386114
    [TBL] [Abstract][Full Text] [Related]  

  • 23. 6th Meeting of the European Society of Oncological Urology.
    Govorov A
    Expert Rev Anticancer Ther; 2009 Apr; 9(4):397-9. PubMed ID: 19374594
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU guidelines.
    Stenzl A; Cowan NC; De Santis M; Kuczyk MA; Merseburger AS; Ribal MJ; Sherif A; Witjes JA;
    Eur Urol; 2011 Jun; 59(6):1009-18. PubMed ID: 21454009
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Potential role for metformin in urologic oncology.
    Sayyid RK; Fleshner NE
    Investig Clin Urol; 2016 May; 57(3):157-64. PubMed ID: 27195314
    [TBL] [Abstract][Full Text] [Related]  

  • 26. European Association of Urology Guidelines on Upper Urinary Tract Urothelial Cell Carcinoma: 2015 Update.
    Rouprêt M; Babjuk M; Compérat E; Zigeuner R; Sylvester RJ; Burger M; Cowan NC; Böhle A; Van Rhijn BW; Kaasinen E; Palou J; Shariat SF
    Eur Urol; 2015 Nov; 68(5):868-79. PubMed ID: 26188393
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Recent advances in immuno-oncology and its application to urological cancers.
    Mataraza JM; Gotwals P
    BJU Int; 2016 Oct; 118(4):506-14. PubMed ID: 27123757
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Highlights from the Society of Urologic Oncology, 5th Annual Meeting, December 3-4, 2004, Bethesda, Maryland, United States of America.
    Grubb RL; Behari A; Kim CM; Williams CR; Linehan WM; Coleman JA
    J Urol; 2005 Dec; 174(6):2330-3. PubMed ID: 16280834
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Novel therapies for advanced urologic cancers.
    Heidenreich A
    Curr Opin Urol; 2020 Jul; 30(4):594-601. PubMed ID: 32453002
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [EAU guidelines on prostate cancer. Part I: screening, diagnosis, and treatment of clinically localised disease].
    Heidenreich A; Bellmunt J; Bolla M; Joniau S; Mason M; Matveev V; Mottet N; Schmid HP; van der Kwast T; Wiegel T; Zattoni F
    Actas Urol Esp; 2011 Oct; 35(9):501-14. PubMed ID: 21757259
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Food and Drug Administration process for development and approval of drugs and radiopharmaceuticals: treatments in urologic oncology.
    Ning YM; Maher VE
    Urol Oncol; 2015 Mar; 33(3):137-42. PubMed ID: 25613202
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The importance of palliative care in urology.
    Brierly RD; O'Brien TS
    Urol Int; 2008; 80(1):13-8. PubMed ID: 18204227
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Maximizing outcomes in genitourinary cancers across the treatment continuum.
    Fitzpatrick JM; Bellmunt J; Dreicer R; Fleshner NE; Logothetis CJ; Moul JW; Tombal B; Zlotta A
    BJU Int; 2011 Apr; 107 Suppl 2():1-12. PubMed ID: 21382149
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of previous radiotherapy for prostate cancer on clinical outcomes of patients with bladder cancer.
    Yee DS; Shariat SF; Lowrance WT; Sterbis JR; Vora KC; Bochner BH; Donat SM; Herr HW; Dalbagni G; Sandhu JS
    J Urol; 2010 May; 183(5):1751-6. PubMed ID: 20299035
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Congress of the American Society of Urology (ASU), San Antonio (Texas), May 15-20, 1993].
    Boiteux JP
    Bull Cancer; 1994 Jan; 81(1):70-3. PubMed ID: 7524820
    [No Abstract]   [Full Text] [Related]  

  • 36. Differences in time to disease progression do not predict for cancer-specific survival in patients receiving immediate or deferred androgen-deprivation therapy for prostate cancer: final results of EORTC randomized trial 30891 with 12 years of follow-up.
    Studer UE; Whelan P; Wimpissinger F; Casselman J; de Reijke TM; Knönagel H; Loidl W; Isorna S; Sundaram SK; Collette L;
    Eur Urol; 2014 Nov; 66(5):829-38. PubMed ID: 23932338
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Chemotherapy in urologic oncology].
    Deville JL
    Prog Urol; 2011 Nov; 21(11):816-21. PubMed ID: 22032608
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The continued debate: intermittent vs. continuous hormonal ablation for metastatic prostate cancer.
    Gleave M; Klotz L; Taneja SS
    Urol Oncol; 2009; 27(1):81-6. PubMed ID: 19111804
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Potential and limitations of diffusion-weighted magnetic resonance imaging in kidney, prostate, and bladder cancer including pelvic lymph node staging: a critical analysis of the literature.
    Giannarini G; Petralia G; Thoeny HC
    Eur Urol; 2012 Feb; 61(2):326-40. PubMed ID: 22000497
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Progress and summary of recent congress: ASCO-GU, EAU, AUA, ASCO about the medical management of locally advanced or metastatic kidney cancer].
    Patard JJ; Escudier B; Paparel P; Neuzillet Y; Long JA; Baumert H; Correas JM; Lang H; Poissonnier L; Rioux-Leclercq N; Soulié M;
    Prog Urol; 2010 Mar; 20 Suppl 1():S11-5. PubMed ID: 20493436
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.